- Home
- KALA vs APRE Comparison
KALA vs APRE Comparison
Compare KALA & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KALA | APRE |
|---|---|---|
| Founded | 2009 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7M | 6.9M |
| IPO Year | 2017 | 2019 |
Fundamental Metrics
Financial Performance| Metric | KALA | APRE |
|---|---|---|
| Price | $0.56 | $0.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $31.50 | $5.00 |
| AVG Volume (30 Days) | ★ 20.4M | 72.6K |
| Earning Date | 11-19-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $488,239.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.51 | $0.90 |
| 52 Week High | $20.60 | $5.00 |
Technical Indicators
Market Signals| Indicator | KALA | APRE |
|---|---|---|
| Relative Strength Index (RSI) | 37.14 | 34.44 |
| Support Level | $0.57 | $0.91 |
| Resistance Level | $0.72 | $1.02 |
| Average True Range (ATR) | 0.08 | 0.05 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 20.52 | 20.50 |
Price Performance
Historical ComparisonAbout KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
About APRE Aprea Therapeutics Inc.
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.